MedTrace Logo

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

NCT04314986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-16

No results posted yet for this study

Summary

A study to assess multiple ascending doses of AR882 in healthy adult males.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Cohort 1: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

DRUG

Cohort 2: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days.

DRUG

Cohort 3: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

DRUG

Cohort 4: AR882 or placebo

AR882 or matching placebo administered once daily for 10 days

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-28
Primary Completion
2019-09-18
Completion
2019-09-18
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314986 on ClinicalTrials.gov